Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An observational study investigating the effectiveness, safety, and costs of switching to dual therapy with dolutegravir plus rilpivirine in treatment-experienced patients with HIV infections.

Trial Profile

An observational study investigating the effectiveness, safety, and costs of switching to dual therapy with dolutegravir plus rilpivirine in treatment-experienced patients with HIV infections.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Dolutegravir (Primary) ; Rilpivirine (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Sep 2017 New trial record
    • 01 Aug 2017 Results published in the Annals of Pharmacotherapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top